Kissei Pharmaceutical Co., Ltd. - Product Pipeline Review - 2014

Published: Sep, 2014 | Pages: 65 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Kissei Pharmaceutical Co., Ltd. - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Kissei Pharmaceutical Co., Ltd. - Product Pipeline Review - 2014', provides an overview of the Kissei Pharmaceutical Co., Ltd.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Kissei Pharmaceutical Co., Ltd.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Kissei Pharmaceutical Co., Ltd. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Kissei Pharmaceutical Co., Ltd.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Kissei Pharmaceutical Co., Ltd.'s pipeline products

Reasons to buy

- Evaluate Kissei Pharmaceutical Co., Ltd.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Kissei Pharmaceutical Co., Ltd. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Kissei Pharmaceutical Co., Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Kissei Pharmaceutical Co., Ltd. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Kissei Pharmaceutical Co., Ltd.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Kissei Pharmaceutical Co., Ltd. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Kissei Pharmaceutical Co., Ltd. Snapshot 7
Kissei Pharmaceutical Co., Ltd. Overview 7
Key Information 7
Key Facts 7
Kissei Pharmaceutical Co., Ltd. - Research and Development Overview 8
Key Therapeutic Areas 8
Kissei Pharmaceutical Co., Ltd. - Pipeline Review 11
Pipeline Products by Stage of Development 11
Pipeline Products - Monotherapy 12
Pipeline Products - Combination Treatment Modalities 13
Pipeline Products - Partnered Products 14
Partnered Products/Combination Treatment Modalities 15
Kissei Pharmaceutical Co., Ltd. - Pipeline Products Glance 16
Kissei Pharmaceutical Co., Ltd. - Late Stage Pipeline Products 16
Pre-Registration Products/Combination Treatment Modalities 16
Phase III Products/Combination Treatment Modalities 17
Kissei Pharmaceutical Co., Ltd. - Clinical Stage Pipeline Products 18
Phase II Products/Combination Treatment Modalities 18
Phase I Products/Combination Treatment Modalities 19
Kissei Pharmaceutical Co., Ltd. - Early Stage Pipeline Products 20
Preclinical Products/Combination Treatment Modalities 20
Discovery Products/Combination Treatment Modalities 21
Kissei Pharmaceutical Co., Ltd. - Drug Profiles 22
mitiglinide 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
KPS-0373 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
sucroferric oxyhydroxide 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
(remogliflozin etabonate + metformin hydrochloride) 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
bedoradrine sulfate 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
KLH-2109 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
KUX-1151 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
KWA-0711 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
ozagrel 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
remogliflozin etabonate 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
YS-110 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
KEA-0477 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
AS-192426900 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
AS-192781900 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
AS-193280400 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
KGO-2142 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
KGO-2173 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
KOM-1962 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
KTA-439 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Small Molecules to Inhibit SGLT1 for Postprandial Hyperglycemia 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
KTA-574 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Kissei Pharmaceutical Co., Ltd. - Pipeline Analysis 48
Kissei Pharmaceutical Co., Ltd. - Pipeline Products by Target 48
Kissei Pharmaceutical Co., Ltd. - Pipeline Products by Route of Administration 50
Kissei Pharmaceutical Co., Ltd. - Pipeline Products by Molecule Type 51
Kissei Pharmaceutical Co., Ltd. - Pipeline Products by Mechanism of Action 52
Kissei Pharmaceutical Co., Ltd. - Recent Pipeline Updates 54
Kissei Pharmaceutical Co., Ltd. - Dormant Projects 58
Kissei Pharmaceutical Co., Ltd. - Discontinued Pipeline Products 59
Discontinued Pipeline Product Profiles 59
diquafosol tetrasodium 59
KGA-3235 59
KLS-0611 59
remogliflozin etabonate 59
ritobegron 60
VX-745 60
Kissei Pharmaceutical Co., Ltd. - Company Statement 61
Kissei Pharmaceutical Co., Ltd. - Locations And Subsidiaries 62
Head Office 62
Other Locations & Subsidiaries 62
Appendix 64
Methodology 64
Coverage 64
Secondary Research 64
Primary Research 64
Expert Panel Validation 64
Contact Us 65
Disclaimer 65

List of Tables
Kissei Pharmaceutical Co., Ltd., Key Information 7
Kissei Pharmaceutical Co., Ltd., Key Facts 7
Kissei Pharmaceutical Co., Ltd. - Pipeline by Indication, 2014 10
Kissei Pharmaceutical Co., Ltd. - Pipeline by Stage of Development, 2014 11
Kissei Pharmaceutical Co., Ltd. - Monotherapy Products in Pipeline, 2014 12
Kissei Pharmaceutical Co., Ltd. - Combination Treatment Modalities in Pipeline, 2014 13
Kissei Pharmaceutical Co., Ltd. - Partnered Products in Pipeline, 2014 14
Kissei Pharmaceutical Co., Ltd. - Partnered Products/ Combination Treatment Modalities, 2014 15
Kissei Pharmaceutical Co., Ltd. - Pre-Registration, 2014 16
Kissei Pharmaceutical Co., Ltd. - Phase III, 2014 17
Kissei Pharmaceutical Co., Ltd. - Phase II, 2014 18
Kissei Pharmaceutical Co., Ltd. - Phase I, 2014 19
Kissei Pharmaceutical Co., Ltd. - Preclinical, 2014 20
Kissei Pharmaceutical Co., Ltd. - Discovery, 2014 21
Kissei Pharmaceutical Co., Ltd. - Pipeline by Target, 2014 49
Kissei Pharmaceutical Co., Ltd. - Pipeline by Route of Administration, 2014 50
Kissei Pharmaceutical Co., Ltd. - Pipeline by Molecule Type, 2014 51
Kissei Pharmaceutical Co., Ltd. - Pipeline Products by Mechanism of Action, 2014 53
Kissei Pharmaceutical Co., Ltd. - Recent Pipeline Updates, 2014 54
Kissei Pharmaceutical Co., Ltd. - Dormant Developmental Projects,2014 58
Kissei Pharmaceutical Co., Ltd. - Discontinued Pipeline Products, 2014 59
Kissei Pharmaceutical Co., Ltd., Other Locations 62
Kissei Pharmaceutical Co., Ltd., Subsidiaries 63